Yüklüyor......
Gardos pathway to sickle cell therapies?
In this issue of Blood, Ataga and colleagues report that treatment of sickle cell disease patients with senicapoc, a Gardos channel inhibitor, reduces the number of dehydrated cells, increases hemoglobin levels, and diminishes hemolysis.
Kaydedildi:
| Yazar: | |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Society of Hematology
2008
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2288713/ https://ncbi.nlm.nih.gov/pubmed/18434967 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-01-135350 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|